REG - Mediclinic Intnl plc - Holding(s) in Company

Morgan StanleyAnnouncement

29/01/2019 15:35

RNS Number : 4206O
Mediclinic International plc
29 January 2019
 


 
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company" or the "Group")
 
29 January 2019
 
 
Notification of Major Interest in Mediclinic International plc shares
 



1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:


Mediclinic International plc.
 




1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)




Non-UK issuer








2. Reason for the notification (please mark the appropriate box or boxes with an "X")




An acquisition or disposal of voting rights


X




An acquisition or disposal of financial instruments








An event changing the breakdown of voting rights








Other (please specify)iii:








3. Details of person subject to the notification obligation




Name


Coronation Asset Management (Pty) Ltd acting as discretionary investment manager on behalf of managed portfolios.




City and country of registered office (if applicable)


Cape Town, South Africa




4. Full name of shareholder(s) (if different from 3.)v




Name


N/A




City and country of registered office (if applicable)








5. Date on which the threshold was crossed or reached:


29/01/2019




6. Date on which issuer notified (DD/MM/YYYY):


29/01/2019




7. Total positions of person(s) subject to the notification obligation








% of voting rights attached to shares (total of 8. A)


% of voting rights through financial instruments

(total of 8.B 1 + 8.B 2)


Total of both in % (8.A + 8.B)


Total number of voting rights of issuer




Resulting situation on the date on which threshold was crossed or reached


2.82






2.82


737 243 810




Position of previous notification (if
applicable)


3.98






3.98
















 



8. Notified details of the resulting situation on the date on which the threshold was crossed or reached




A: Voting rights attached to shares




Class/type of

shares
ISIN code (if possible)


Number of voting rights


% of voting rights




Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)


Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)


Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)


Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)




GB00B8HX8Z88


20 825 908






2.82




















































SUBTOTAL 8. A


20 825 908


2.82




 
 




B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))




Type of financial instrument


Expiration

date


Exercise/

Conversion Period


Number of voting rights that may be acquired if the instrument is
exercised/converted.


% of voting rights














































































SUBTOTAL 8. B 1












 
 




B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))




Type of financial instrument


Expiration

date


Exercise/

Conversion Period


Physical or cash
settlement


Number of voting rights


% of voting rights






























































































SUBTOTAL 8.B.2





























 



9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an "X")




Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii








Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)


X




Name


% of voting rights if it equals or is higher than the notifiable threshold


% of voting rights through financial instruments if it equals or is higher than the notifiable threshold


Total of both if it equals or is higher than the notifiable threshold




Coronation Fund Managers Ltd
















Coronation Investment Management SA (Pty) Ltd
















Coronation Asset Management (Pty) Ltd


2.82






2.82














































10. In case of proxy voting, please identify:




Name of the proxy holder








The number and % of voting rights held








The date until which the voting rights will be held














11. Additional information
















 



Place of completion


Cape Town, South Africa




Date of completion


29/01/2019



 
 
Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.
 
For further information, please contact:
 
Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569
 
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
 
Media queries
FTI Consulting
Brett Pollard/Debbie Scott - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
 
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com 
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLUKAARKOAAUAR